Ryoo and collaborators conducted a comprehensive analysis to assess the effectiveness and safety of IFN (systemic or inhaled IFN-α, -β, and -λ) treatment in patients with COVID-19, stratified by the severity of their clinical condition. The gene discussed is IFNA1; the disease is COVID-19.